Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity
Identifieur interne : 000763 ( Istex/Corpus ); précédent : 000762; suivant : 000764Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity
Auteurs : S. Shichijo ; N. Keicho ; H. T. Long ; T. Quy ; N. C. Phi ; L. D. Ha ; V. V. Ban ; S. Itoyama ; C. Hu ; N. Komatsu ; T. Kirikae ; F. Kirikae ; S. Shirasawa ; M. Kaji ; T. Fukuda ; M. Sata ; T. Kuratsuji ; K. Itoh ; T. SasazukiSource :
- Tissue Antigens [ 0001-2815 ] ; 2004-11.
English descriptors
- Teeft :
- Absorption test, Clin chem, Clinical manifestations, Contact persons, Coronavirus, Corresponding peptide, Dose dependency, Elisa, Epitope, Flowmetry analysis, Fluorescence intensity, Fluorescence intensity fluorescence intensity, Fluorescence intensity patient, Giai phong, Healthy donors, Higher levels, Humoral responses, Immunogenic, Immunogenic epitopes, Immunogenic regions, Japanese patients, Kinetic studies, Kurume, Kurume university school, Luminex, Luminex corp, Luminex reactivities, Negative controls, None peptides, Novel coronavirus, Nucleocapsid, Nucleocapsid protein, Peptide, Peptide peptide sequence, Plate shaker, Positions peptide, Protective vaccine, Reactive, Representative results, Respiratory syndrome, Respiratory syndrome coronavirus, Rheumatoid arthritis, Room temperature, Saan district, Same times, Sars, Sars patients, Sars peptides, Serum dilution, Serum samples, Shichijo, Significant levels, Syndrome, Synthetic peptides, Systemic lupus erythematosus, Taiwanese patients, Times dilution, Tissue antigens, Vaccine.
Abstract
Abstract: In order to determine highly immunogenic severe acute respiratory syndrome coronavirus (SARS‐CoV) epitope peptides capable of inducing long‐lasting immunity, we first screened immunoglobulin‐G (IgG) antibodies reactive to 197 different overlapping 15‐mers from the SARS‐CoV proteins in the sera of three infected patients. Forty‐two peptides among them were reactive to the sera from all three patients. Consequently, we tested for the reactivity of these 42 peptides to patients' sera (n = 45) at 6‐month post‐infection. The significantly higher levels of IgG antibodies specific to three (S791, M207 and N161) of 42 peptides were detectable in the post‐infection sera from 23 (51%), 27 (60%) and 19 (42%) of 45 patients, respectively. These three peptides, recognized by their long‐lasting immunity, may provide a better understanding of the immunogenicity of SARS‐CoV.
Url:
DOI: 10.1111/j.1399-0039.2004.00314.x
Links to Exploration step
ISTEX:0144A752526A448C35F9BF8FE17D22DA1834C23DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity</title><author><name sortKey="Shichijo, S" sort="Shichijo, S" uniqKey="Shichijo S" first="S." last="Shichijo">S. Shichijo</name><affiliation><mods:affiliation>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Keicho, N" sort="Keicho, N" uniqKey="Keicho N" first="N." last="Keicho">N. Keicho</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Long, H T" sort="Long, H T" uniqKey="Long H" first="H. T." last="Long">H. T. Long</name><affiliation><mods:affiliation>National Institute of Hygiene and Epidemiology, Yersin, Hanoi, Vietnam</mods:affiliation></affiliation></author><author><name sortKey="Quy, T" sort="Quy, T" uniqKey="Quy T" first="T." last="Quy">T. Quy</name><affiliation><mods:affiliation>Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</mods:affiliation></affiliation></author><author><name sortKey="Phi, N C" sort="Phi, N C" uniqKey="Phi N" first="N. C." last="Phi">N. C. Phi</name><affiliation><mods:affiliation>Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</mods:affiliation></affiliation></author><author><name sortKey="Ha, L D" sort="Ha, L D" uniqKey="Ha L" first="L. D." last="Ha">L. D. Ha</name><affiliation><mods:affiliation>Institute for Clinical Research in Tropical Medicine, Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</mods:affiliation></affiliation></author><author><name sortKey="Ban, V V" sort="Ban, V V" uniqKey="Ban V" first="V. V." last="Ban">V. V. Ban</name><affiliation><mods:affiliation>Hanoi French Hospital, Phuong Mai, Hanoi, Vietnam</mods:affiliation></affiliation></author><author><name sortKey="Itoyama, S" sort="Itoyama, S" uniqKey="Itoyama S" first="S." last="Itoyama">S. Itoyama</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hu, C" sort="Hu, C" uniqKey="Hu C" first="C." last="Hu">C. Hu</name><affiliation><mods:affiliation>Taipei Municipal Jen‐Ai Hospital, SaAn District, Taipei, Taiwan</mods:affiliation></affiliation></author><author><name sortKey="Komatsu, N" sort="Komatsu, N" uniqKey="Komatsu N" first="N." last="Komatsu">N. Komatsu</name><affiliation><mods:affiliation>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kirikae, T" sort="Kirikae, T" uniqKey="Kirikae T" first="T." last="Kirikae">T. Kirikae</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kirikae, F" sort="Kirikae, F" uniqKey="Kirikae F" first="F." last="Kirikae">F. Kirikae</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Shirasawa, S" sort="Shirasawa, S" uniqKey="Shirasawa S" first="S." last="Shirasawa">S. Shirasawa</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kaji, M" sort="Kaji, M" uniqKey="Kaji M" first="M." last="Kaji">M. Kaji</name><affiliation><mods:affiliation>Kurume Medical Center, Kokubu‐machi, Kurume, Japan</mods:affiliation></affiliation></author><author><name sortKey="Fukuda, T" sort="Fukuda, T" uniqKey="Fukuda T" first="T." last="Fukuda">T. Fukuda</name><affiliation><mods:affiliation>Kurume Medical Center, Kokubu‐machi, Kurume, Japan</mods:affiliation></affiliation></author><author><name sortKey="Sata, M" sort="Sata, M" uniqKey="Sata M" first="M." last="Sata">M. Sata</name><affiliation><mods:affiliation>Department of Internal Medicine, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kuratsuji, T" sort="Kuratsuji, T" uniqKey="Kuratsuji T" first="T." last="Kuratsuji">T. Kuratsuji</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Itoh, K" sort="Itoh, K" uniqKey="Itoh K" first="K." last="Itoh">K. Itoh</name><affiliation><mods:affiliation>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Sasazuki, T" sort="Sasazuki, T" uniqKey="Sasazuki T" first="T." last="Sasazuki">T. Sasazuki</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: *T. SasazukiInternational Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0144A752526A448C35F9BF8FE17D22DA1834C23D</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1111/j.1399-0039.2004.00314.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-3462P0ZW-R/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000763</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000763</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity</title><author><name sortKey="Shichijo, S" sort="Shichijo, S" uniqKey="Shichijo S" first="S." last="Shichijo">S. Shichijo</name><affiliation><mods:affiliation>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Keicho, N" sort="Keicho, N" uniqKey="Keicho N" first="N." last="Keicho">N. Keicho</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Long, H T" sort="Long, H T" uniqKey="Long H" first="H. T." last="Long">H. T. Long</name><affiliation><mods:affiliation>National Institute of Hygiene and Epidemiology, Yersin, Hanoi, Vietnam</mods:affiliation></affiliation></author><author><name sortKey="Quy, T" sort="Quy, T" uniqKey="Quy T" first="T." last="Quy">T. Quy</name><affiliation><mods:affiliation>Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</mods:affiliation></affiliation></author><author><name sortKey="Phi, N C" sort="Phi, N C" uniqKey="Phi N" first="N. C." last="Phi">N. C. Phi</name><affiliation><mods:affiliation>Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</mods:affiliation></affiliation></author><author><name sortKey="Ha, L D" sort="Ha, L D" uniqKey="Ha L" first="L. D." last="Ha">L. D. Ha</name><affiliation><mods:affiliation>Institute for Clinical Research in Tropical Medicine, Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</mods:affiliation></affiliation></author><author><name sortKey="Ban, V V" sort="Ban, V V" uniqKey="Ban V" first="V. V." last="Ban">V. V. Ban</name><affiliation><mods:affiliation>Hanoi French Hospital, Phuong Mai, Hanoi, Vietnam</mods:affiliation></affiliation></author><author><name sortKey="Itoyama, S" sort="Itoyama, S" uniqKey="Itoyama S" first="S." last="Itoyama">S. Itoyama</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hu, C" sort="Hu, C" uniqKey="Hu C" first="C." last="Hu">C. Hu</name><affiliation><mods:affiliation>Taipei Municipal Jen‐Ai Hospital, SaAn District, Taipei, Taiwan</mods:affiliation></affiliation></author><author><name sortKey="Komatsu, N" sort="Komatsu, N" uniqKey="Komatsu N" first="N." last="Komatsu">N. Komatsu</name><affiliation><mods:affiliation>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kirikae, T" sort="Kirikae, T" uniqKey="Kirikae T" first="T." last="Kirikae">T. Kirikae</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kirikae, F" sort="Kirikae, F" uniqKey="Kirikae F" first="F." last="Kirikae">F. Kirikae</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Shirasawa, S" sort="Shirasawa, S" uniqKey="Shirasawa S" first="S." last="Shirasawa">S. Shirasawa</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kaji, M" sort="Kaji, M" uniqKey="Kaji M" first="M." last="Kaji">M. Kaji</name><affiliation><mods:affiliation>Kurume Medical Center, Kokubu‐machi, Kurume, Japan</mods:affiliation></affiliation></author><author><name sortKey="Fukuda, T" sort="Fukuda, T" uniqKey="Fukuda T" first="T." last="Fukuda">T. Fukuda</name><affiliation><mods:affiliation>Kurume Medical Center, Kokubu‐machi, Kurume, Japan</mods:affiliation></affiliation></author><author><name sortKey="Sata, M" sort="Sata, M" uniqKey="Sata M" first="M." last="Sata">M. Sata</name><affiliation><mods:affiliation>Department of Internal Medicine, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kuratsuji, T" sort="Kuratsuji, T" uniqKey="Kuratsuji T" first="T." last="Kuratsuji">T. Kuratsuji</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author><author><name sortKey="Itoh, K" sort="Itoh, K" uniqKey="Itoh K" first="K." last="Itoh">K. Itoh</name><affiliation><mods:affiliation>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Sasazuki, T" sort="Sasazuki, T" uniqKey="Sasazuki T" first="T." last="Sasazuki">T. Sasazuki</name><affiliation><mods:affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: *T. SasazukiInternational Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Tissue Antigens</title><title level="j" type="alt">TISSUE ANTIGENS</title><idno type="ISSN">0001-2815</idno><idno type="eISSN">1399-0039</idno><imprint><biblScope unit="vol">64</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="600">600</biblScope><biblScope unit="page" to="607">607</biblScope><biblScope unit="page-count">8</biblScope><publisher>Munksgaard International Publishers</publisher><pubPlace>Oxford, UK; Malden, USA</pubPlace><date type="published" when="2004-11">2004-11</date></imprint><idno type="ISSN">0001-2815</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-2815</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Absorption test</term><term>Clin chem</term><term>Clinical manifestations</term><term>Contact persons</term><term>Coronavirus</term><term>Corresponding peptide</term><term>Dose dependency</term><term>Elisa</term><term>Epitope</term><term>Flowmetry analysis</term><term>Fluorescence intensity</term><term>Fluorescence intensity fluorescence intensity</term><term>Fluorescence intensity patient</term><term>Giai phong</term><term>Healthy donors</term><term>Higher levels</term><term>Humoral responses</term><term>Immunogenic</term><term>Immunogenic epitopes</term><term>Immunogenic regions</term><term>Japanese patients</term><term>Kinetic studies</term><term>Kurume</term><term>Kurume university school</term><term>Luminex</term><term>Luminex corp</term><term>Luminex reactivities</term><term>Negative controls</term><term>None peptides</term><term>Novel coronavirus</term><term>Nucleocapsid</term><term>Nucleocapsid protein</term><term>Peptide</term><term>Peptide peptide sequence</term><term>Plate shaker</term><term>Positions peptide</term><term>Protective vaccine</term><term>Reactive</term><term>Representative results</term><term>Respiratory syndrome</term><term>Respiratory syndrome coronavirus</term><term>Rheumatoid arthritis</term><term>Room temperature</term><term>Saan district</term><term>Same times</term><term>Sars</term><term>Sars patients</term><term>Sars peptides</term><term>Serum dilution</term><term>Serum samples</term><term>Shichijo</term><term>Significant levels</term><term>Syndrome</term><term>Synthetic peptides</term><term>Systemic lupus erythematosus</term><term>Taiwanese patients</term><term>Times dilution</term><term>Tissue antigens</term><term>Vaccine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: In order to determine highly immunogenic severe acute respiratory syndrome coronavirus (SARS‐CoV) epitope peptides capable of inducing long‐lasting immunity, we first screened immunoglobulin‐G (IgG) antibodies reactive to 197 different overlapping 15‐mers from the SARS‐CoV proteins in the sera of three infected patients. Forty‐two peptides among them were reactive to the sera from all three patients. Consequently, we tested for the reactivity of these 42 peptides to patients' sera (n = 45) at 6‐month post‐infection. The significantly higher levels of IgG antibodies specific to three (S791, M207 and N161) of 42 peptides were detectable in the post‐infection sera from 23 (51%), 27 (60%) and 19 (42%) of 45 patients, respectively. These three peptides, recognized by their long‐lasting immunity, may provide a better understanding of the immunogenicity of SARS‐CoV.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>peptide</json:string><json:string>sars</json:string><json:string>fluorescence intensity</json:string><json:string>coronavirus</json:string><json:string>times dilution</json:string><json:string>kurume</json:string><json:string>shichijo</json:string><json:string>tissue antigens</json:string><json:string>immunogenic</json:string><json:string>luminex</json:string><json:string>reactive</json:string><json:string>contact persons</json:string><json:string>nucleocapsid</json:string><json:string>respiratory syndrome</json:string><json:string>serum dilution</json:string><json:string>elisa</json:string><json:string>epitope</json:string><json:string>sars peptides</json:string><json:string>room temperature</json:string><json:string>representative results</json:string><json:string>sars patients</json:string><json:string>novel coronavirus</json:string><json:string>significant levels</json:string><json:string>plate shaker</json:string><json:string>respiratory syndrome coronavirus</json:string><json:string>syndrome</json:string><json:string>vaccine</json:string><json:string>negative controls</json:string><json:string>serum samples</json:string><json:string>immunogenic regions</json:string><json:string>healthy donors</json:string><json:string>higher levels</json:string><json:string>luminex corp</json:string><json:string>japanese patients</json:string><json:string>absorption test</json:string><json:string>kurume university school</json:string><json:string>fluorescence intensity patient</json:string><json:string>giai phong</json:string><json:string>fluorescence intensity fluorescence intensity</json:string><json:string>dose dependency</json:string><json:string>flowmetry analysis</json:string><json:string>positions peptide</json:string><json:string>taiwanese patients</json:string><json:string>rheumatoid arthritis</json:string><json:string>systemic lupus erythematosus</json:string><json:string>same times</json:string><json:string>luminex reactivities</json:string><json:string>saan district</json:string><json:string>synthetic peptides</json:string><json:string>peptide peptide sequence</json:string><json:string>immunogenic epitopes</json:string><json:string>corresponding peptide</json:string><json:string>kinetic studies</json:string><json:string>none peptides</json:string><json:string>humoral responses</json:string><json:string>clinical manifestations</json:string><json:string>nucleocapsid protein</json:string><json:string>protective vaccine</json:string><json:string>clin chem</json:string></teeft></keywords><author><json:item><name>S. Shichijo</name><affiliations><json:string>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</json:string></affiliations></json:item><json:item><name>N. Keicho</name><affiliations><json:string>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>H.T. Long</name><affiliations><json:string>National Institute of Hygiene and Epidemiology, Yersin, Hanoi, Vietnam</json:string></affiliations></json:item><json:item><name>T. Quy</name><affiliations><json:string>Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</json:string></affiliations></json:item><json:item><name>N.C. Phi</name><affiliations><json:string>Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</json:string></affiliations></json:item><json:item><name>L.D. Ha</name><affiliations><json:string>Institute for Clinical Research in Tropical Medicine, Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</json:string></affiliations></json:item><json:item><name>V.V. Ban</name><affiliations><json:string>Hanoi French Hospital, Phuong Mai, Hanoi, Vietnam</json:string></affiliations></json:item><json:item><name>S. Itoyama</name><affiliations><json:string>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>C.‐J. Hu</name><affiliations><json:string>Taipei Municipal Jen‐Ai Hospital, SaAn District, Taipei, Taiwan</json:string></affiliations></json:item><json:item><name>N. Komatsu</name><affiliations><json:string>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</json:string></affiliations></json:item><json:item><name>T. Kirikae</name><affiliations><json:string>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>F. Kirikae</name><affiliations><json:string>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>S. Shirasawa</name><affiliations><json:string>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>M. Kaji</name><affiliations><json:string>Kurume Medical Center, Kokubu‐machi, Kurume, Japan</json:string></affiliations></json:item><json:item><name>T. Fukuda</name><affiliations><json:string>Kurume Medical Center, Kokubu‐machi, Kurume, Japan</json:string></affiliations></json:item><json:item><name>M. Sata</name><affiliations><json:string>Department of Internal Medicine, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</json:string></affiliations></json:item><json:item><name>T. Kuratsuji</name><affiliations><json:string>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</json:string></affiliations></json:item><json:item><name>K. Itoh</name><affiliations><json:string>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</json:string></affiliations></json:item><json:item><name>T. Sasazuki</name><affiliations><json:string>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</json:string><json:string>Correspondence address: *T. SasazukiInternational Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>IgG</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>long‐lasting immunity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>SARS</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>structural protein</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>synthetic peptides</value></json:item></subject><articleId><json:string>TAN314</json:string></articleId><arkIstex>ark:/67375/WNG-3462P0ZW-R</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>chapter</json:string></originalGenre><abstract>Abstract: In order to determine highly immunogenic severe acute respiratory syndrome coronavirus (SARS‐CoV) epitope peptides capable of inducing long‐lasting immunity, we first screened immunoglobulin‐G (IgG) antibodies reactive to 197 different overlapping 15‐mers from the SARS‐CoV proteins in the sera of three infected patients. Forty‐two peptides among them were reactive to the sera from all three patients. Consequently, we tested for the reactivity of these 42 peptides to patients' sera (n = 45) at 6‐month post‐infection. The significantly higher levels of IgG antibodies specific to three (S791, M207 and N161) of 42 peptides were detectable in the post‐infection sera from 23 (51%), 27 (60%) and 19 (42%) of 45 patients, respectively. These three peptides, recognized by their long‐lasting immunity, may provide a better understanding of the immunogenicity of SARS‐CoV.</abstract><qualityIndicators><score>7.541</score><pdfWordCount>4029</pdfWordCount><pdfCharCount>26106</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>8</pdfPageCount><pdfPageSize>595 x 782 pts</pdfPageSize><pdfWordsPerPage>504</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>126</abstractWordCount><abstractCharCount>882</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity</title><pmid><json:string>15496204</json:string></pmid><genre><json:string>other</json:string></genre><host><title>Tissue Antigens</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1399-0039</json:string></doi><issn><json:string>0001-2815</json:string></issn><eissn><json:string>1399-0039</json:string></eissn><publisherId><json:string>TAN</json:string></publisherId><volume>64</volume><issue>5</issue><pages><first>600</first><last>607</last><total>8</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2003</json:string><json:string>2004</json:string></date><geogName></geogName><orgName><json:string>Hanoi French Hospital, Phuong Mai, Hanoi, Vietnam</json:string><json:string>WHO</json:string><json:string>Kurume University Hospital and Kurume Medical Center</json:string><json:string>Luminex Corp., Austin</json:string><json:string>National Institute of Hygiene and Epidemiology</json:string><json:string>American Peptide Company, Inc</json:string><json:string>Institute for Clinical Research</json:string><json:string>Japan, Toyama, Shinjuku, Tokyo, Japan</json:string><json:string>Hanoi French Hospital and Bach Mai Hospital</json:string><json:string>Department of Internal Medicine, Kurume University School of Medicine, Asahimachi, Kurume, Fukuoka, Japan Correspondence</json:string><json:string>Luminex Corp.</json:string><json:string>Kurume Medical Center</json:string><json:string>International Medical Center</json:string><json:string>Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</json:string><json:string>Department of Immunology, Kurume University School of Medicine, Asahi</json:string><json:string>Snow Brand Milk Products Co.</json:string><json:string>Vector Laboratory Inc</json:string><json:string>Millipore Co., Bedford</json:string><json:string>Sasazuki International Medical Center</json:string><json:string>World Health Organization</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>N. Komatsu</json:string><json:string>Phuong Thuy</json:string><json:string>S. Shichijo</json:string><json:string>Peptide</json:string><json:string>V.V. Ban</json:string><json:string>N. Keicho</json:string><json:string>J. Hu</json:string><json:string>M. Kaji</json:string><json:string>T. Quy</json:string><json:string>M. Sata</json:string><json:string>S. Shirasawa</json:string><json:string>N.C. Phi</json:string><json:string>Nguyen Thu</json:string><json:string>F. Kirikae</json:string><json:string>T. Kuratsuji</json:string><json:string>Akira</json:string><json:string>S. Itoyama</json:string><json:string>K. Itoh</json:string><json:string>T. Sasazuki</json:string><json:string>Masamichi Koujiro</json:string><json:string>T. Kirikae</json:string><json:string>T. Fukuda</json:string><json:string>L.D. Ha</json:string></persName><placeName><json:string>Hanoi</json:string><json:string>Fukuoka</json:string><json:string>Vietnam</json:string><json:string>Taiwan</json:string><json:string>Japan</json:string><json:string>Denmark</json:string><json:string>Taipei</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>369, 1300</json:string><json:string>189, 3160</json:string><json:string>706, 3237</json:string><json:string>Gao et al.</json:string><json:string>Wang et al.</json:string><json:string>111, 12099</json:string><json:string>612, 2224</json:string><json:string>324, 1035</json:string><json:string>Shichijo et al</json:string><json:string>368, 1314</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-3462P0ZW-R</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pathology</json:string><json:string>2 - immunology</json:string><json:string>2 - cell biology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - immunology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Genetics</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Biochemistry</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - General Medicine</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1111/j.1399-0039.2004.00314.x</json:string></doi><id>0144A752526A448C35F9BF8FE17D22DA1834C23D</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-3462P0ZW-R/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-3462P0ZW-R/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-3462P0ZW-R/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity</title><title level="a" type="short">Shichijo et al : Assessment of SARS peptides recognized by long‐lasting immunity</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Munksgaard International Publishers</publisher><pubPlace>Oxford, UK; Malden, USA</pubPlace><date type="published" when="2004-11"></date></publicationStmt><notesStmt><note type="content-type" subtype="brief-communication" source="chapter" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="brief-communication"><analytic><title level="a" type="main">Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity</title><title level="a" type="short">Shichijo et al : Assessment of SARS peptides recognized by long‐lasting immunity</title><author xml:id="author-0000"><persName><forename type="first">S.</forename><surname>Shichijo</surname></persName><affiliation><orgName type="department">Department of Immunology</orgName><orgName type="institution">Kurume University School of Medicine</orgName><address><addrLine>Asahi‐machi</addrLine><addrLine>Kurume, Fukuoka, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">N.</forename><surname>Keicho</surname></persName><affiliation><orgName type="institution">International Medical Center of Japan</orgName><address><addrLine>Toyama</addrLine><addrLine>Shinjuku, Tokyo, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">H.T.</forename><surname>Long</surname></persName><affiliation><orgName type="institution">National Institute of Hygiene and Epidemiology</orgName><address><addrLine>Yersin</addrLine><addrLine>Hanoi, Vietnam</addrLine></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">T.</forename><surname>Quy</surname></persName><affiliation><orgName type="institution">Bach Mai Hospital</orgName><address><addrLine>Giai Phong</addrLine><addrLine>Hanoi, Vietnam</addrLine></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">N.C.</forename><surname>Phi</surname></persName><affiliation><orgName type="institution">Bach Mai Hospital</orgName><address><addrLine>Giai Phong</addrLine><addrLine>Hanoi, Vietnam</addrLine></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">L.D.</forename><surname>Ha</surname></persName><affiliation><orgName type="institution">Institute for Clinical Research in Tropical Medicine</orgName><orgName type="institution">Bach Mai Hospital</orgName><address><addrLine>Giai Phong</addrLine><addrLine>Hanoi, Vietnam</addrLine></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">V.V.</forename><surname>Ban</surname></persName><affiliation><orgName type="institution">Hanoi French Hospital</orgName><address><addrLine>Phuong Mai</addrLine><addrLine>Hanoi, Vietnam</addrLine></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first">S.</forename><surname>Itoyama</surname></persName><affiliation><orgName type="institution">International Medical Center of Japan</orgName><address><addrLine>Toyama</addrLine><addrLine>Shinjuku, Tokyo, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0008"><persName><forename type="first">C.‐J.</forename><surname>Hu</surname></persName><affiliation><orgName type="institution">Taipei Municipal Jen‐Ai Hospital</orgName><address><addrLine>SaAn District</addrLine><addrLine>Taipei, Taiwan</addrLine></address></affiliation></author><author xml:id="author-0009"><persName><forename type="first">N.</forename><surname>Komatsu</surname></persName><affiliation><orgName type="department">Department of Immunology</orgName><orgName type="institution">Kurume University School of Medicine</orgName><address><addrLine>Asahi‐machi</addrLine><addrLine>Kurume, Fukuoka, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0010"><persName><forename type="first">T.</forename><surname>Kirikae</surname></persName><affiliation><orgName type="institution">International Medical Center of Japan</orgName><address><addrLine>Toyama</addrLine><addrLine>Shinjuku, Tokyo, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0011"><persName><forename type="first">F.</forename><surname>Kirikae</surname></persName><affiliation><orgName type="institution">International Medical Center of Japan</orgName><address><addrLine>Toyama</addrLine><addrLine>Shinjuku, Tokyo, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0012"><persName><forename type="first">S.</forename><surname>Shirasawa</surname></persName><affiliation><orgName type="institution">International Medical Center of Japan</orgName><address><addrLine>Toyama</addrLine><addrLine>Shinjuku, Tokyo, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0013"><persName><forename type="first">M.</forename><surname>Kaji</surname></persName><affiliation><orgName type="institution">Kurume Medical Center</orgName><address><addrLine>Kokubu‐machi</addrLine><addrLine>Kurume, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0014"><persName><forename type="first">T.</forename><surname>Fukuda</surname></persName><affiliation><orgName type="institution">Kurume Medical Center</orgName><address><addrLine>Kokubu‐machi</addrLine><addrLine>Kurume, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0015"><persName><forename type="first">M.</forename><surname>Sata</surname></persName><affiliation><orgName type="division">Department of Internal Medicine</orgName><orgName type="institution">Kurume University School of Medicine</orgName><address><addrLine>Asahi‐machi</addrLine><addrLine>Kurume, Fukuoka, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0016"><persName><forename type="first">T.</forename><surname>Kuratsuji</surname></persName><affiliation><orgName type="institution">International Medical Center of Japan</orgName><address><addrLine>Toyama</addrLine><addrLine>Shinjuku, Tokyo, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0017"><persName><forename type="first">K.</forename><surname>Itoh</surname></persName><affiliation><orgName type="department">Department of Immunology</orgName><orgName type="institution">Kurume University School of Medicine</orgName><address><addrLine>Asahi‐machi</addrLine><addrLine>Kurume, Fukuoka, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><author xml:id="author-0018" role="corresp"><persName><forename type="first">T.</forename><surname>Sasazuki</surname></persName><affiliation><orgName type="institution">International Medical Center of Japan</orgName><address><addrLine>Toyama</addrLine><addrLine>Shinjuku, Tokyo, Japan</addrLine><country key="JP" xml:lang="en">JAPAN</country></address></affiliation></author><idno type="istex">0144A752526A448C35F9BF8FE17D22DA1834C23D</idno><idno type="ark">ark:/67375/WNG-3462P0ZW-R</idno><idno type="DOI">10.1111/j.1399-0039.2004.00314.x</idno><idno type="unit">TAN314</idno><idno type="toTypesetVersion">file:TAN.TAN314.pdf</idno></analytic><monogr><title level="j" type="main">Tissue Antigens</title><title level="j" type="alt">TISSUE ANTIGENS</title><idno type="pISSN">0001-2815</idno><idno type="eISSN">1399-0039</idno><idno type="book-DOI">10.1111/(ISSN)1399-0039</idno><idno type="book-part-DOI">10.1111/tan.2004.64.issue-5</idno><idno type="product">TAN</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">64</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="600">600</biblScope><biblScope unit="page" to="607">607</biblScope><biblScope unit="page-count">8</biblScope><publisher>Munksgaard International Publishers</publisher><pubPlace>Oxford, UK; Malden, USA</pubPlace><date type="published" when="2004-11"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><p><hi rend="bold">Abstract: </hi> In order to determine highly immunogenic severe acute respiratory syndrome coronavirus (SARS‐CoV) epitope peptides capable of inducing long‐lasting immunity, we first screened immunoglobulin‐G (IgG) antibodies reactive to 197 different overlapping 15‐mers from the SARS‐CoV proteins in the sera of three infected patients. Forty‐two peptides among them were reactive to the sera from all three patients. Consequently, we tested for the reactivity of these 42 peptides to patients' sera (<hi rend="italic">n</hi> = 45) at 6‐month post‐infection. The significantly higher levels of IgG antibodies specific to three (S791, M207 and N161) of 42 peptides were detectable in the post‐infection sera from 23 (51%), 27 (60%) and 19 (42%) of 45 patients, respectively. These three peptides, recognized by their long‐lasting immunity, may provide a better understanding of the immunogenicity of SARS‐CoV.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">IgG</term><term xml:id="k2">long‐lasting immunity</term><term xml:id="k3">SARS</term><term xml:id="k4">structural protein</term><term xml:id="k5">synthetic peptides </term></keywords><keywords rend="tocHeading1"><term>Brief communications</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-3462P0ZW-R/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Munksgaard International Publishers</publisherName><publisherLoc>Oxford, UK; Malden, USA</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1399-0039</doi><issn type="print">0001-2815</issn><issn type="electronic">1399-0039</issn><idGroup><id type="product" value="TAN"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="TISSUE ANTIGENS">Tissue Antigens</title></titleGroup></publicationMeta><publicationMeta level="part" position="11005"><doi origin="wiley">10.1111/tan.2004.64.issue-5</doi><numberingGroup><numbering type="journalVolume" number="64">64</numbering><numbering type="journalIssue" number="5">5</numbering></numberingGroup><coverDate startDate="2004-11">November 2004</coverDate></publicationMeta><publicationMeta level="unit" type="chapter" position="0060000" status="forIssue"><doi origin="wiley">10.1111/j.1399-0039.2004.00314.x</doi><idGroup><id type="unit" value="TAN314"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="tocHeading1">Brief communications</title></titleGroup><eventGroup><event type="firstOnline" date="2004-10-20"></event><event type="publishedOnlineFinalForm" date="2004-10-20"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-01"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-10"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-04"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="600">600</numbering><numbering type="pageLast" number="607">607</numbering></numberingGroup><correspondenceTo>
*T. Sasazuki
International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:TAN.TAN314.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 19 March 2004, accepted for publication 7 July 2004</unparsedEditorialHistory><countGroup><count type="figureTotal" number="5"></count><count type="tableTotal" number="1"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="17"></count><count type="wordTotal" number="4643"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity</title><title type="shortAuthors">Shichijo et al : Assessment of SARS peptides recognized by long‐lasting immunity</title><title type="short">Shichijo et al : Assessment of SARS peptides recognized by long‐lasting immunity</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>S.</givenNames><familyName>Shichijo</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>N.</givenNames><familyName>Keicho</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a3"><personName><givenNames>H.T.</givenNames><familyName>Long</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a4"><personName><givenNames>T.</givenNames><familyName>Quy</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a4"><personName><givenNames>N.C.</givenNames><familyName>Phi</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a5"><personName><givenNames>L.D.</givenNames><familyName>Ha</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a6"><personName><givenNames>V.V.</givenNames><familyName>Ban</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a2"><personName><givenNames>S.</givenNames><familyName>Itoyama</familyName></personName></creator><creator creatorRole="author" xml:id="cr9" affiliationRef="#a7"><personName><givenNames>C.‐J.</givenNames><familyName>Hu</familyName></personName></creator><creator creatorRole="author" xml:id="cr10" affiliationRef="#a1"><personName><givenNames>N.</givenNames><familyName>Komatsu</familyName></personName></creator><creator creatorRole="author" xml:id="cr11" affiliationRef="#a2"><personName><givenNames>T.</givenNames><familyName>Kirikae</familyName></personName></creator><creator creatorRole="author" xml:id="cr12" affiliationRef="#a2"><personName><givenNames>F.</givenNames><familyName>Kirikae</familyName></personName></creator><creator creatorRole="author" xml:id="cr13" affiliationRef="#a2"><personName><givenNames>S.</givenNames><familyName>Shirasawa</familyName></personName></creator><creator creatorRole="author" xml:id="cr14" affiliationRef="#a8"><personName><givenNames>M.</givenNames><familyName>Kaji</familyName></personName></creator><creator creatorRole="author" xml:id="cr15" affiliationRef="#a8"><personName><givenNames>T.</givenNames><familyName>Fukuda</familyName></personName></creator><creator creatorRole="author" xml:id="cr16" affiliationRef="#a9"><personName><givenNames>M.</givenNames><familyName>Sata</familyName></personName></creator><creator creatorRole="author" xml:id="cr17" affiliationRef="#a2"><personName><givenNames>T.</givenNames><familyName>Kuratsuji</familyName></personName></creator><creator creatorRole="author" xml:id="cr18" affiliationRef="#a1"><personName><givenNames>K.</givenNames><familyName>Itoh</familyName></personName></creator><creator creatorRole="author" xml:id="cr19" affiliationRef="#a2" corresponding="yes"><personName><givenNames>T.</givenNames><familyName>Sasazuki</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="JP"><unparsedAffiliation>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="JP"><unparsedAffiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</unparsedAffiliation></affiliation><affiliation xml:id="a3"><unparsedAffiliation>National Institute of Hygiene and Epidemiology, Yersin, Hanoi, Vietnam</unparsedAffiliation></affiliation><affiliation xml:id="a4"><unparsedAffiliation>Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</unparsedAffiliation></affiliation><affiliation xml:id="a5"><unparsedAffiliation>Institute for Clinical Research in Tropical Medicine, Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</unparsedAffiliation></affiliation><affiliation xml:id="a6"><unparsedAffiliation>Hanoi French Hospital, Phuong Mai, Hanoi, Vietnam</unparsedAffiliation></affiliation><affiliation xml:id="a7"><unparsedAffiliation>Taipei Municipal Jen‐Ai Hospital, SaAn District, Taipei, Taiwan</unparsedAffiliation></affiliation><affiliation xml:id="a8" countryCode="JP"><unparsedAffiliation>Kurume Medical Center, Kokubu‐machi, Kurume, Japan</unparsedAffiliation></affiliation><affiliation xml:id="a9" countryCode="JP"><unparsedAffiliation>Department of Internal Medicine, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">IgG</keyword><keyword xml:id="k2">long‐lasting immunity</keyword><keyword xml:id="k3">SARS</keyword><keyword xml:id="k4">structural protein</keyword><keyword xml:id="k5">synthetic peptides </keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Abstract: </b> In order to determine highly immunogenic severe acute respiratory syndrome coronavirus (SARS‐CoV) epitope peptides capable of inducing long‐lasting immunity, we first screened immunoglobulin‐G (IgG) antibodies reactive to 197 different overlapping 15‐mers from the SARS‐CoV proteins in the sera of three infected patients. Forty‐two peptides among them were reactive to the sera from all three patients. Consequently, we tested for the reactivity of these 42 peptides to patients' sera (<i>n</i> = 45) at 6‐month post‐infection. The significantly higher levels of IgG antibodies specific to three (S791, M207 and N161) of 42 peptides were detectable in the post‐infection sera from 23 (51%), 27 (60%) and 19 (42%) of 45 patients, respectively. These three peptides, recognized by their long‐lasting immunity, may provide a better understanding of the immunogenicity of SARS‐CoV.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Shichijo et al : Assessment of SARS peptides recognized by long‐lasting immunity</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity</title></titleInfo><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Shichijo</namePart><affiliation>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Keicho</namePart><affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.T.</namePart><namePart type="family">Long</namePart><affiliation>National Institute of Hygiene and Epidemiology, Yersin, Hanoi, Vietnam</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Quy</namePart><affiliation>Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.C.</namePart><namePart type="family">Phi</namePart><affiliation>Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.D.</namePart><namePart type="family">Ha</namePart><affiliation>Institute for Clinical Research in Tropical Medicine, Bach Mai Hospital, Giai Phong, Hanoi, Vietnam</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V.V.</namePart><namePart type="family">Ban</namePart><affiliation>Hanoi French Hospital, Phuong Mai, Hanoi, Vietnam</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Itoyama</namePart><affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.‐J.</namePart><namePart type="family">Hu</namePart><affiliation>Taipei Municipal Jen‐Ai Hospital, SaAn District, Taipei, Taiwan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Komatsu</namePart><affiliation>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Kirikae</namePart><affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Kirikae</namePart><affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Shirasawa</namePart><affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Kaji</namePart><affiliation>Kurume Medical Center, Kokubu‐machi, Kurume, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Fukuda</namePart><affiliation>Kurume Medical Center, Kokubu‐machi, Kurume, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Sata</namePart><affiliation>Department of Internal Medicine, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Kuratsuji</namePart><affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Itoh</namePart><affiliation>Department of Immunology, Kurume University School of Medicine, Asahi‐machi, Kurume, Fukuoka, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Sasazuki</namePart><affiliation>International Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</affiliation><affiliation>Correspondence address: *T. SasazukiInternational Medical Center of Japan, Toyama, Shinjuku, Tokyo, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="other" displayLabel="chapter" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</genre><originInfo><publisher>Munksgaard International Publishers</publisher><place><placeTerm type="text">Oxford, UK; Malden, USA</placeTerm></place><dateIssued encoding="w3cdtf">2004-11</dateIssued><edition>Received 19 March 2004, accepted for publication 7 July 2004</edition><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">5</extent><extent unit="tables">1</extent><extent unit="formulas">0</extent><extent unit="references">17</extent><extent unit="linksCrossRef">0</extent><extent unit="words">4643</extent></physicalDescription><abstract lang="en">Abstract: In order to determine highly immunogenic severe acute respiratory syndrome coronavirus (SARS‐CoV) epitope peptides capable of inducing long‐lasting immunity, we first screened immunoglobulin‐G (IgG) antibodies reactive to 197 different overlapping 15‐mers from the SARS‐CoV proteins in the sera of three infected patients. Forty‐two peptides among them were reactive to the sera from all three patients. Consequently, we tested for the reactivity of these 42 peptides to patients' sera (n = 45) at 6‐month post‐infection. The significantly higher levels of IgG antibodies specific to three (S791, M207 and N161) of 42 peptides were detectable in the post‐infection sera from 23 (51%), 27 (60%) and 19 (42%) of 45 patients, respectively. These three peptides, recognized by their long‐lasting immunity, may provide a better understanding of the immunogenicity of SARS‐CoV.</abstract><subject lang="en"><genre>keywords</genre><topic>IgG</topic><topic>long‐lasting immunity</topic><topic>SARS</topic><topic>structural protein</topic><topic>synthetic peptides</topic></subject><relatedItem type="host"><titleInfo><title>Tissue Antigens</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0001-2815</identifier><identifier type="eISSN">1399-0039</identifier><identifier type="DOI">10.1111/(ISSN)1399-0039</identifier><identifier type="PublisherID">TAN</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>600</start><end>607</end><total>8</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Identification of a novel coronavirus in patients with severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Drosten</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Gunther</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Preiser</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Drosten C, Gunther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003: 348: 1967–76.DOI: 10.1056/NEJMoa030747</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1967</start><end>76</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1967</start><end>76</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>A novel coronavirus associated with severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">TG</namePart><namePart type="family">Ksiazek</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Erdman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CS</namePart><namePart type="family">Goldsmith</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ksiazek TG, Erdman D, Goldsmith CS et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003: 348: 1953–66.DOI: 10.1056/NEJMoa030781</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1953</start><end>66</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>1953</start><end>66</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Characterization of a novel coronavirus associated with severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Rota</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MS</namePart><namePart type="family">Oberste</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SS</namePart><namePart type="family">Monroe</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rota PA, Oberste MS, Monroe SS et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003: 300: 1394–9.DOI: 10.1126/science.1085952</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>300</number></detail><extent unit="pages"><start>1394</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>300</number></detail><extent unit="pages"><start>1394</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Assessment of immunoreactive synthetic peptides from the structural proteins of severe acute respiratory syndrome coronavirus</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Wen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wang J, Wen J, Li J et al. Assessment of immunoreactive synthetic peptides from the structural proteins of severe acute respiratory syndrome coronavirus. Clin Chem 2003: 49: 1989–96.DOI: 10.1373/clinchem.2003.023184</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>1989</start><end>96</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Chem</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>1989</start><end>96</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Cavanagh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cavanagh D. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol 2003: 32: 567–82.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>567</start><end>82</end></extent></part><relatedItem type="host"><titleInfo><title>Avian Pathol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>567</start><end>82</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Effects of a SARS‐associated coronavirus vaccine in monkeys</title></titleInfo><name type="personal"><namePart type="given">W</namePart><namePart type="family">Gao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Tamin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Soloff</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gao W, Tamin A, Soloff A et al. Effects of a SARS‐associated coronavirus vaccine in monkeys. Lancet 2003: 362: 1895–6.DOI: 10.1016/S0140-6736(03)14962-8</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>362</number></detail><extent unit="pages"><start>1895</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>362</number></detail><extent unit="pages"><start>1895</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Angiotensin‐converting enzyme 2 is a functional receptor for the SARS coronavirus</title></titleInfo><name type="personal"><namePart type="given">W</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Moore</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Vasilieva</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Li W, Moore MJ, Vasilieva N et al. Angiotensin‐converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003: 426: 450–4.DOI: 10.1038/nature02145</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>426</number></detail><extent unit="pages"><start>450</start><end>4</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>426</number></detail><extent unit="pages"><start>450</start><end>4</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Expression of the monoclonal antibody against nucleocapsid antigen of SARS‐associated coronavirus in autopsy tissues from SARS patients</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">He</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YQ</namePart><namePart type="family">Ding</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">XY</namePart><namePart type="family">Che</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">He L, Ding YQ, Che XY et al. Expression of the monoclonal antibody against nucleocapsid antigen of SARS‐associated coronavirus in autopsy tissues from SARS patients. Di Yi Jun Yi Da Xue Xue Bao 2003: 23: 1128–30.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1128</start><end>30</end></extent></part><relatedItem type="host"><titleInfo><title>Di Yi Jun Yi Da Xue Xue Bao</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1128</start><end>30</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>New multiplexed flow cytometric assay to measure anti‐peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Komatsu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Shichijo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Nakagawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Itoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Komatsu N, Shichijo S, Nakagawa M, Itoh K. New multiplexed flow cytometric assay to measure anti‐peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 2004: 64: 535–546.DOI: 10.1080/00365510410007008</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>535</start><end>546</end></extent></part><relatedItem type="host"><titleInfo><title>Scand J Clin Lab Invest</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>535</start><end>546</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Analysis of false‐positive associated with antibody tests for SARS‐CoV in SLE patients</title></titleInfo><name type="personal"><namePart type="given">YS</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Shen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SH</namePart><namePart type="family">Sun</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wang YS, Shen H, Sun SH et al. Analysis of false‐positive associated with antibody tests for SARS‐CoV in SLE patients. Shi Yan Sheng Wu Xue Bao 2003: 36: 314–7.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>314</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Shi Yan Sheng Wu Xue Bao</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>314</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Antibodies to SARS‐like virus hint at repeated infections</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Pearson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pearson H. Antibodies to SARS‐like virus hint at repeated infections. Nature 2004: 427: 185.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>427</number></detail><extent unit="pages"><start>185</start></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>427</number></detail><extent unit="pages"><start>185</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Dynamic observation IgG and IgM antibodies in patients with severe acute respiratory syndrome</title></titleInfo><name type="personal"><namePart type="given">JH</namePart><namePart type="family">Zhuang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">XZ</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LY</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhuang JH, Huang XZ, Zhou Q, Lin LY, Lin L. Dynamic observation IgG and IgM antibodies in patients with severe acute respiratory syndrome. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2003: 15: 579–81.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>579</start><end>81</end></extent></part><relatedItem type="host"><titleInfo><title>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>579</start><end>81</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan</title></titleInfo><name type="personal"><namePart type="given">PR</namePart><namePart type="family">Hsueh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CH</namePart><namePart type="family">Hsiao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SH</namePart><namePart type="family">Yeh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hsueh PR, Hsiao CH, Yeh SH et al. Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan. Emerg Infect Dis 2003: 9: 1163–7.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>1163</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Emerg Infect Dis</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>1163</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Detection of the anti‐SARS coronavirus‐specific antibody levels in 156 SARS patients</title></titleInfo><name type="personal"><namePart type="given">HB</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JH</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">XL</namePart><namePart type="family">Ouyang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wang HB, Liu JH, Ouyang XL et al. Detection of the anti‐SARS coronavirus‐specific antibody levels in 156 SARS patients. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003: 11: 441–3.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>441</start><end>3</end></extent></part><relatedItem type="host"><titleInfo><title>Zhongguo Shi Yan Xue Ye Xue Za Zhi</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>441</start><end>3</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Multiplexed quantification of human IgG, IgA, and IgM with the FlowMetrixTM system</title></titleInfo><name type="personal"><namePart type="given">RF</namePart><namePart type="family">Gordon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RL</namePart><namePart type="family">McDade</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gordon RF, McDade RL. Multiplexed quantification of human IgG, IgA, and IgM with the FlowMetrixTM system. Clin Chem 1997: 43: 1799–801.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>1799</start><end>801</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Chem</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>1799</start><end>801</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Severe acute respiratory syndrome (SARS)</title></titleInfo><name type="corporate"><namePart>WHO</namePart></name><genre>journal-article</genre><note type="citation/reference">WHO. Severe acute respiratory syndrome (SARS). Wkly Epidemiol Rec 2003: 78: 81–3.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>81</start><end>3</end></extent></part><relatedItem type="host"><titleInfo><title>Wkly Epidemiol Rec</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>81</start><end>3</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>IgG reactive to CTL‐directed epitopes of self‐antigens is either lacking or unbalanced in atopic dermatitis patients</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Kawamoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Yamada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ohkouchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kawamoto N, Yamada A, Ohkouchi S et al. IgG reactive to CTL‐directed epitopes of self‐antigens is either lacking or unbalanced in atopic dermatitis patients. Tissue Antigens 2003: 61: 1–10.DOI: 10.1034/j.1399-0039.2003.610101.x</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1</start><end>10</end></extent></part><relatedItem type="host"><titleInfo><title>Tissue Antigens</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1</start><end>10</end></extent></part></relatedItem></relatedItem><identifier type="istex">0144A752526A448C35F9BF8FE17D22DA1834C23D</identifier><identifier type="ark">ark:/67375/WNG-3462P0ZW-R</identifier><identifier type="DOI">10.1111/j.1399-0039.2004.00314.x</identifier><identifier type="ArticleID">TAN314</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-3462P0ZW-R/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000763 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000763 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:0144A752526A448C35F9BF8FE17D22DA1834C23D
|texte= Assessment of synthetic peptides of severe acute respiratory syndrome coronavirus recognized by long‐lasting immunity
}}
| This area was generated with Dilib version V0.6.33. |  |